Ardizzoni A - Search Results

1

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A. Buti S, et al. Among authors: ardizzoni a. Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. Lancet Oncol. 2014. PMID: 24988929 No abstract available.

2

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crinò L. Cappuzzo F, et al. Among authors: ardizzoni a. Lung Cancer. 2003 Aug;41(2):227-31. doi: 10.1016/s0169-5002(03)00189-2. Lung Cancer. 2003. PMID: 12871787 Clinical Trial.

3

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A. Tiseo M, et al. Among authors: ardizzoni a. Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. doi: 10.2174/1568011043482106. Curr Med Chem Anticancer Agents. 2004. PMID: 15032719 Review.

4

Predictors of clinical response of non-small cell cancer to gefitinib.

Ardizzoni A, Tiseo M. Ardizzoni A, et al. JAMA. 2004 Apr 7;291(13):1563; author reply 1563-4. doi: 10.1001/jama.291.13.1563-a. JAMA. 2004. PMID: 15069041 No abstract available.

5

Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.

Ardizzoni A, Scolaro T, Mereu C, Cafferata MA, Tixi L, Bacigalupo A, Tiseo M, Monetti F, Rosso R. Ardizzoni A, et al. Am J Clin Oncol. 2005 Feb;28(1):58-64. doi: 10.1097/01.coc.0000139486.24747.26. Am J Clin Oncol. 2005. PMID: 15685036 Clinical Trial.

6

Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

Ardizzoni A, Tiseo M. Ardizzoni A, et al. J Chemother. 2004 Nov;16 Suppl 4:104-7. doi: 10.1179/joc.2004.16.Supplement-1.104. J Chemother. 2004. PMID: 15688623 Review.

7

CASE 1. Complete remission to corticosteroids in an octreotide-refractory thymoma.

Tiseo M, Monetti F, Ferrarini M, Serrano J, Chiaramondia M, Ardizzoni A. Tiseo M, et al. Among authors: ardizzoni a. J Clin Oncol. 2005 Mar 1;23(7):1578-9. doi: 10.1200/JCO.2005.03.115. J Clin Oncol. 2005. PMID: 15735133 No abstract available.

8

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.

Musolino A, Perrone MA, Michiara M, Delnevo D, Franciosi V, Di Blasio B, Ceci G, Camisa R, Ardizzoni A, Cocconi G. Musolino A, et al. Among authors: ardizzoni a. Cancer. 2005 May 15;103(10):2109-17. doi: 10.1002/cncr.21024. Cancer. 2005. PMID: 15803492 Free article.

9

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. Loprevite M, et al. Among authors: ardizzoni a. Oncol Res. 2005;15(1):39-48. doi: 10.3727/096504005775082066. Oncol Res. 2005. PMID: 15839304

10

A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes.

Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B, Capelletti M, Savi M, Neri TM, Ardizzoni A. Musolino A, et al. Among authors: ardizzoni a. Breast Cancer Res Treat. 2005 May;91(2):203-5. doi: 10.1007/s10549-004-7704-4. Breast Cancer Res Treat. 2005. PMID: 15868448

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

499 results

Search Page

Filters